Shandong Xinhua Pharmaceutical Co Ltd
SZSE:000756
Shandong Xinhua Pharmaceutical Co Ltd
Free Cash Flow
Shandong Xinhua Pharmaceutical Co Ltd
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Shandong Xinhua Pharmaceutical Co Ltd
SZSE:000756
|
Free Cash Flow
¥155.2m
|
CAGR 3-Years
150%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Free Cash Flow
¥4.2B
|
CAGR 3-Years
26%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Free Cash Flow
¥1B
|
CAGR 3-Years
47%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
21%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Free Cash Flow
¥5.5B
|
CAGR 3-Years
29%
|
CAGR 5-Years
11%
|
CAGR 10-Years
16%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Free Cash Flow
¥3.6B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
22%
|
CAGR 10-Years
10%
|
|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
Free Cash Flow
-¥1.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Shandong Xinhua Pharmaceutical Co Ltd
Glance View
In the industrious province of Shandong, China, Shandong Xinhua Pharmaceutical Co. Ltd. emerges as a notable player in the pharmaceutical landscape. Established in 1943, the company has grown into a comprehensive pharmaceutical enterprise with a significant presence both domestically and internationally. At its core, Shandong Xinhua is devoted to the research, development, and manufacture of active pharmaceutical ingredients (APIs), finished dosages, and chemical intermediates. The firm's strength lies in its diverse range of products, with pain management and anti-infectives being standout categories. Their strategic focus on innovation is evident in their state-of-the-art R&D facilities, which fuel continuous product development, ensuring they meet high regulatory standards and cater to evolving market demands. The journey of Shandong Xinhua is one of strategic evolution, with a steadfast commitment to quality and sustainability. This narrative is reflected in their robust revenue streams derived from both domestic sales and the lucrative export markets across over 50 countries. The company's business model hinges on creating value through efficient manufacturing processes and leveraging economies of scale, which enhances their competitive edge in the global market. With an eye on future growth, they've also been investing in digitalization to streamline operations and enhance productivity. As the pharmaceutical sector continues to expand, Shandong Xinhua Pharmaceutical Co. Ltd. is poised to capitalize on emerging opportunities, underpinned by its solid foundation and innovative thrust.
See Also
What is Shandong Xinhua Pharmaceutical Co Ltd's Free Cash Flow?
Free Cash Flow
155.2m
CNY
Based on the financial report for Dec 31, 2024, Shandong Xinhua Pharmaceutical Co Ltd's Free Cash Flow amounts to 155.2m CNY.
What is Shandong Xinhua Pharmaceutical Co Ltd's Free Cash Flow growth rate?
Free Cash Flow CAGR 3Y
150%
The average annual Free Cash Flow growth rates for Shandong Xinhua Pharmaceutical Co Ltd have been 150% over the past three years .
You don't have any saved screeners yet